retatrutide status fda Before Approval: What Nurses Need to Know Retatrutide, an experimental weight-loss drug,

Reported side effects are similar to other GLP-1 type drugs mainly mild to moderate gastrointestinal symptoms like nausea or diarrhea, especially during dose escalation

Regulatory Frameworks and Supply Dynamics: In December 2025, the FDA approved the first oral GLP-1 for weight loss-Novo Nordisk's once-daily semaglutide pill, which launched in January 2026, significantly expanding accessibility for patients averse to injections [3]

This synergistic action was mediated by activation of the Keap1/Nrf2/GPX4 antioxidant axis, which suppressed lipid peroxidation, mitigated ferroptosis, and preserved ovarian function, as evidenced by normalized hormone profiles and follicle counts [160]

Soliqua 100/33 (insulin glargine and lixisenatide injection) [package insert]

Phase 2 trial data published in the New England Journal of Medicine in 2023 generated considerable interest, though retatrutide has not yet received MHRA or EMA marketing authorisation and remains unavailable through NHS or regulated private prescribing pathways